A Phase 4 interventional study of ezetimibe (+) simvastatin and simvastatin in Atherosclerosis, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ezetimibe in Atherosclerosis — 2 open to participants now, 2 under way, none of them phase 3. Ezetimibe · Atherosclerosis.
Among the 22 studies testing ezetimibe in Atherosclerosis, this one is the 4th largest by enrollment, is the only one that started in 2005, is one of 9 in phase 4, and was the 4th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →2 of the 22 studies testing ezetimibe in Atherosclerosis are open now, in 2 countries. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 55+
Universidade do Porto · Sites in Portugal
Ages 18–75
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 367 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 121 across the 22 interventional studies. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
14 studies in Atherosclerosis by Organon & Co.: none open now, none under way, none of them phase 3. Of 14 finished, 2 (14%) have results posted.
Among the 14 studies in Atherosclerosis by Organon & Co., this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2005, is one of 8 in phase 4, and was the 1st registered.
Organon & Co.’s Atherosclerosis studies by the year they started, since 2002.
1 of the studies testing ezetimibe in Atherosclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07839741Universidade do PortoLDL Cholesterol Reduction Following Ezetimibe Initiation | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing ezetimibe in Atherosclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 14 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In patients with coronary artery disease and a LDL-C level between 2.5 mmol/L and 5.0 mmol/L on a stable (> 4 weeks) statin starting dose (simvastatin 20 mg or atorvastatin 10 mg), investigate what the LCL-C lowering efficacy is of doubling the statin dose (to 40 mg simvastatin or 20 mg atorvastatin) versus a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. It is postulated that more patients reach their LDL-C treatment goal with the combination tablet compared to doubling the starting dose. Furthermore, the effect of both treatment regimens on other lipid parameters, safety and LDL-subfractions will be measured.
Patients with simvastatin 20 mg or atorvastatin 10 mg were randomized to (1) double statin dose (to 40 mg simvastatin or 20 mg atorvastatin) or (2) switch to a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: Active comparator
Drug: simvastatin · Drug: atorvastatin
Arm 2: Drug
Drug: ezetimibe (+) simvastatin
Drug pages: Ezetimibe · Simvastatin
Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
Also known as: MK0653A, Vytorin®, INEGY™
Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
Also known as: MK0733, Zocor®
20 mg atorvastatin once daily for 12 weeks. Tablets
Switching to a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg is superior to doubling the statin dose as demonstrated by the percentage of patients reaching goal after 12 weeks of treatment.
Time frame: after 12 weeks of treatment
Switching to a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg will lower LDL-C more than doubling the statin dose as demonstrated by the percentage change from treated baseline in total and LDL-cholesterol after 12 weeks of treatment.
Time frame: after 12 weeks of treatment
No study locations are listed for this record.
The record gives a start of Nov 2005, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin